MeSH D005910 - glioma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018302:Neuroepithelial neoplasms
0 Companies
0 Drugs
Success rate
D005910:Â
Glioma
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Temozolomide | Temozolomide Accord |  | 2010-03-15 |  |  |
| Hexal | Temozolomide | Temozolomide Hexal |  | 2010-03-15 |  |  |
| medac | Temozolomide | Temomedac |  | 2010-01-25 |  |  |
| Merck & Co | Temozolomide | Temodal |  | 1999-01-26 |  |  |
| Sandoz | Temozolomide | Temozolomide Sandoz |  | 2010-03-15 |  |  |
| Sun Pharmaceutical Industries | Temozolomide | Temozolomide Sun |  | 2011-07-13 |  |  |
| Teva | Temozolomide | Temozolomide Teva |  | 2010-01-28 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
61%85/139
Phase 2
9%14/148
Phase 3
13%2/15
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use